RE:The potential oncology collaboration..Should have listed on HKSE instead of NASDAQ. We'd have $3bil mkt cap by now. ;-)
I think a deal will come fairly quickly on the back of just announcing they will be filing at least one pivotal for a specific cancer. They can then get full value on that with a partner and the partner can get first look at anything else, knowing full well they'll have to pay "market" at that time on whatever that indication is. I am not totally familiar with Chineses "FDA-like" approval processes but I would think it's like most countries where trials are for specific uses only and based solely on trial data (perhaps globally but I don't know).